David McManus to Cost-Benefit Analysis
This is a "connection" page, showing publications David McManus has written about Cost-Benefit Analysis.
Connection Strength
0.134
-
Beeler Asay GR, Woodruff R, Sanderson DM, Fisher CF, Marks SM, Green VD, Tibbs AM, Hill AN, Haptu HH, McManus D, Paradise RK, Auguste-Nelson C, Cochran JJ. Cost-effectiveness of expanded latent TB infection testing and treatment: Lynn City, Massachusetts, USA. Int J Tuberc Lung Dis. 2024 Jan 01; 28(1):21-28.
Score: 0.048
-
Chen W, Khurshid S, Singer DE, Atlas SJ, Ashburner JM, Ellinor PT, McManus DD, Lubitz SA, Chhatwal J. Cost-effectiveness of Screening for Atrial Fibrillation Using Wearable Devices. JAMA Health Forum. 2022 08; 3(8):e222419.
Score: 0.044
-
Khurshid S, Chen W, Singer DE, Atlas SJ, Ashburner JM, Choi JG, Hur C, Ellinor PT, McManus DD, Chhatwal J, Lubitz SA. Comparative Clinical Effectiveness of Population-Based Atrial Fibrillation Screening Using Contemporary Modalities: A Decision-Analytic Model. J Am Heart Assoc. 2021 09 21; 10(18):e020330.
Score: 0.041